Bristol-Myers Squibb Company with ticker code (BMY) have now 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 94 and 60 calculating the mean target price we have 72.28. Now with the previous closing price of 64.07 this is indicating there is a potential upside of 12.8%. The 50 day MA is 61.38 while the 200 day moving average is 63.26. The market cap for the company is $144,254m. Visit the company website at: https://www.bms.com
The potential market cap would be $162,739m based on the market concensus.
Bristol-Myers Squibb Company develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals; Huyabio; DarwinHealth, Inc; Inspirna; and Bolt Biotherapeutics The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
